PD-L1 Cancer Research Results

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
1031- BCA,    Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer
- vitro+vivo, CRC, HCT116 - vitro+vivo, CRC, SW-620
PD-L1↓, TumCG↓, Zeb1↓, E-cadherin↑, N-cadherin↓, EMT↓,
1037- EA,    Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction
- in-vivo, CRC, NA
AntiTum↑, PD-L1↓,
3141- VitC,    High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
- in-vitro, CRC, HCT116
Glycolysis↓, eff↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   Glycolysis↓, 1,   HK2↓, 1,   LDHA↓, 1,   PKM2↓, 1,   Warburg↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   N-cadherin↓, 1,   Zeb1↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   NF-kB↓, 1,   PD-L1↓, 3,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 3,  

Functional Outcomes ⓘ

AntiTum↑, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
1 Biochanin A
1 Ellagic acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:243  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page